Back to Journals » Drug Design, Development and Therapy » Volume 13

Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy

Total article views   HTML views PDF downloads Totals
8,640 Dovepress* 5,614+ 1,444 7,058
PubMed Central* 3,026 680 3,706
Totals 8,640 2,124 10,764
*Since 8 February 2019

View citations on PubMed Central and Google Scholar